Refractory wtKRAS metastatic colorectal cancer MedDRA version: 14.1 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Conditions
Interventions
Product Name: BIBW2992
Product Code: AFATINIB
Pharmaceutical Form: Tablet
Sponsors
UNICANCER
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Metastatic colorectal cancer expressing the wtKRAS status 2.No previous EGFR targeted therapy. 3.Must have failed a prior regimen containing irinotecan for metastatic disease and a prior regimen containing oxaliplatin for metastatic disease 4.Must have previously received a thymidylate synthase inhibitor (eg, fluorouracil, capecitabine, raltitrexed, or fluorouracil-uracil) at any point for treatment of colorectal cancer (CRC) 5.Life expectancy of at least 3 months. 6.Patient with ECOG = 1 7.Patients aged = 18. 8.Patient with measurable lesions according to RECIST criteria (version 1.1) with spiral CT scan and defined as = 10 mm in longest diameter and 2X the slice thickness for extra nodal lesions and/or > 15 mm in short axis diameter for nodal lesions 9.Patient able to receive adequate oral nutrition of = 1500 calories per day and free of significant nausea and vomiting 10.Patient with adequate organ function: •Absolute neutrophil count (ANC) = 1.5 x 109/L •Haemoglobin = 9 g/dL •Platelets (PTL) = 100 x 109/L •AST/ALT = 2.5 x ULN (= 5 x ULN in case of liver metastases) •GammaGT =65 years) yes F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: 1.Previous EGFR targeted therapy. 2.Mutant KRAS status 3.Prior severe reaction to a monoclonal antibody 4.Clinically relevant cardiovascular abnormalities, as judged by the investigator, such as, but not limited to, uncontrolled hypertension, congestive heart failure NYHA classification > III, unstable angina, myocardial infarction within six months prior to randomisation, or poorly controlled arrhythmia 5.Cardiac left ventricular dysfunction with resting ejection fraction of less than institutional lower limit of normal (if no lower limit of normal is defined in the institution, the lower limit is 50%) 6.Symptomatic brain metastases requiring treatment 7.Major surgery within 28 days or minor surgery within 14 days of the start of the study treatment 8.Radiotherapy less than two weeks prior to the start of the study treatment 9.Systemic chemotherapy, hormonal therapy, immunotherapy = 28 days before study treatment 10.No major comorbidity that may preclude the delivery of treatment or active infection (HIV or chronic hepatitis B or C) or uncontrolled diabetes. 11.Concomitant occurrence of another cancer, or history of cancer within the past five years except in situ carcinoma of the cervix treated or basal cell carcinoma or squamous cell carcinoma. 12.Known pre-existing interstitial lung disease 13.Significant or recent acute gastrointestinal disorders with diarrhea as a major symptom e.g., Crohn’s disease, malabsorption, or CTCAE grade >2 diarrhea of any etiology 14.Pregnant woman or lactating woman. 15.Persons deprived of liberty or under guardianship. 16.Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Non Progression rate at 6 months; Secondary Objective: •Objective response rate based on RECIST v1.1, •Safety and tolerability of afatinib and cetuximab combo, •Progression Free survival (PFS) •Overall survival ;Primary end point(s): The primary endpoint non progression rate will be presented by the percentage of patients without progression at 6 months with the 95% confidence interval.;Timepoint(s) of evaluation of this end point: 6 months | — |
Countries
France
Contacts
Public ContactNourredine AIT-RAHMOUNE
UNICANCER
Outcome results
None listed